Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462187 · ClinicalTrials.gov registry record · Phase 2
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2 study of Genital Warts and Perianal Warts, sponsored by Novan.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 15
- Study locations
NCT02462187: Completed Phase 2 study of Genital Warts and Perianal Warts, sponsored by Novan.
NCT02462187 is a Phase 2 study of Genital Warts and Perianal Warts that has completed, run by Novan. The registered enrollment target is 108 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% lower). The trial reports 15 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462187, a Phase 2 study of Genital Warts and Perianal Warts, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 15
- Study locations
Study Summary
A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
Primary Outcome
Clearance of baseline external genital and perianal warts at or before Week 12 as determined by physical examination by the investigator.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG NVN1000 8% Gel
- DRUG NVN1000 16%
- DRUG NVN1000 24%
Study Locations (15)
Texas
- PPD 128 - Corpus Christi
- PPD 129 - Houston
- PPD 127 - San Antonio
- PPD 131 - Webster
California
- PPD 137 - Fountain Valley
- PPD 140 - Lomita
- PPD 133 - San Diego
Georgia
- PPD 134 - Atlanta
- PPD 139 - Atlanta
- PPD 138 - Roswell
Indiana
- PPD 130 - Indianapolis
Louisiana
- PPD 126 - Metairie
Oregon
- PPD 132 - Portland
Pennsylvania
- PPD 135 - Philadelphia
Washington
- PPD 136 - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-06-12 |
| Est. Completion | 2016-10-17 |
| Phase | Phase 2 |
What the finished NCT02462187 record still lists
NCT02462187 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% lower).
The record links to 2 conditions, with Genital Warts appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT02462187 lists 15 locations in 8 states (Texas, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT02462187 about?
NCT02462187 is a clinical study titled "Topical NVN1000 for the Treatment of External Genital and Perianal Warts". A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
What is the current status of trial NCT02462187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2015-06-12. Estimated completion is 2016-10-17.
What conditions does trial NCT02462187 study?
This clinical trial studies the following conditions: Genital Warts, Perianal Warts.
What interventions are being tested in trial NCT02462187?
The interventions under investigation include: Vehicle (DRUG), NVN1000 8% Gel (DRUG), NVN1000 16% (DRUG), NVN1000 24% (DRUG).
Who is sponsoring clinical trial NCT02462187?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02462187 being conducted?
This trial has 15 study locations across California, Georgia, Indiana, Louisiana, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02462187's enrollment target sits among peer trials
108 640th of 2000 higher than 1,355 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI